Search clinical trials for: TAK-954 Placebo

Total 58176 results

Calithera Biosciences, Inc

Terminated

A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin | Lymphoma, Follicular, Marginal Zone

Korea, Republic of, Japan
Calithera Biosciences, Inc

Terminated

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors

Nonhematologic Neoplasms, Advanced

Japan
Takeda

Completed

Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study

Healthy Volunteers

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

Prostate Cancer

United States
Millennium Pharmaceuticals, Inc.

Terminated

Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematological Malignancies

United States
Takeda

Completed

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Erosive Esophagitis

Japan
Millennium Pharmaceuticals, Inc.

Completed

Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Metastatic Melanoma | Advanced Non-hematologic Malignancies

United States
Takeda

Terminated

Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy

Diabetic Neuropathies
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Takeda

Completed

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Takeda

Terminated

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Poland, Bulgaria, Romania, Canada, Hungary, Slovakia
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
Takeda

Terminated

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

Alzheimer Disease | Healthy Volunteers

United States
Teva takeda

Completed

A Study of TAK-279 in Adults With or Without Kidney Problems

Renal Impairment | Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-103 in Adult With Solid Tumors

Solid Tumors

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
Takeda

Completed

Open-label Study of TAK-875

Diabetes Mellitus

Japan
Takeda

Completed

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Breast Neoplasm | Ovarian Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Renal Neoplasm

United States
Dong-A ST Co., Ltd.

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

Gastritis Acute | Gastritis Chronic

Korea, Republic of
Takeda
Richmond Pharmacology Limited

Completed

Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects

Dose Finding Study
Calithera Biosciences, Inc

Withdrawn

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Advanced Solid Neoplasms | Lymphoma Neoplasms
Weill Medical College of Cornell University

Terminated

Attention Bias Modification Treatment for Anxious Youth (ABMT)

Obsessive-Compulsive Disorder | Generalized Anxiety Disorder | Social Phobia | Separation Anxiety Disorder | Specific Phobia

United States
Millennium Pharmaceuticals, Inc.

Completed

Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants

Healthy Volunteers

United States
MedImmune LLC

Completed

Study to Evaluate the Safety and Efficacy of CAT-354

Asthma

Bulgaria, United Kingdom, Germany, Poland, Romania
Kwang-Ha Yoo
Hanlim Pharm. Co., Ltd.

Completed

Evaluate the Efficacy and Safety of Acute Bronchitis Symptoms Improvement for Bronpass Tab. Compared to Erdos Capsule

Acute Bronchitis

Korea, Republic of
Takeda

Completed

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Healthy Volunteers

United States
Ono Pharma USA Inc

Completed

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Ocular Hypertension (OHT) | Mild Open Angle-glaucoma (OAG)

United States
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-205 for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Japan
Toray Industries, Inc

Completed

Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Taiho Oncology, Inc.

Completed

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Advanced Solid Tumors (Excluding Breast Cancer)

United States
Takeda

Recruiting

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Lennox Gastaut Syndrome (LGS) | Dravet Syndrome (DS)

United States, China, Spain, France, Belgium, Australia, Brazil, Canada, Germany, Greece, Hungary, Italy, Japan, Latvia, Netherlands, Poland, Serbia, Mexico, Russian Federation, Ukraine
MedImmune LLC

Terminated

A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

Moderate Asthma

United Kingdom
Takeda

Recruiting

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Alpha1-Antitrypsin Deficiency

Italy, United States, Poland, Portugal
Presage Biosciences
Takeda

Completed

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

Head and Neck Cancer

United States
Millennium Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer

Cancer

United States
Taiho Oncology, Inc.

Completed

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Refractory Metastatic Gastric Cancer

France, United States, Spain, United Kingdom, Germany, Ireland, Japan, Belgium, Italy, Turkey, Belarus, Israel, Portugal, Russian Federation, Czechia, Poland, Canada, Romania
Taiho Oncology, Inc.

Completed

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE)

Colorectal Cancer

United States, Spain, United Kingdom, Australia, Sweden, Belgium, France, Ireland, Germany, Austria, Japan, Italy, Czechia
Taiho Pharmaceutical Co., Ltd.

Completed

A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Toray Industries, Inc

Completed

Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750

Healthy, Peripheral Neuropathic Pain

United Kingdom
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Seborrheic Dermatitis

United States, Canada
Theravance Biopharma

Terminated

A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects

Gastrointestinal Motility Disorder

United States
Bradley A. McGregor, MD
Calithera Biosciences, Inc

Completed

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Takeda

Completed

A Study of Soticlestat Tablets in Healthy Adults

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of Soticlestat in Adults and Children With Rare Epilepsies (Endymion 1)

Epilepsy | Dravet Syndrome (DS) | Lennox-Gastaut Syndrome (LGS)

United States, Canada, Australia, China, Israel, Poland, Spain, Portugal
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom

Search clinical trials for: TAK-954 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations